Bristol Myers, SystImmune's Iza-Bren hits primary endpoint in Phase 3 PANKU-Lung01 interim analysis in EGFR-mutated NSCLC

Bristol Myers Squibb and SystImmune reported that izalontamab brengitecan (Iza-Bren) hit its primary endpoint in a Phase 3 PANKU-Lung01 interim analysis, with median PFS of 11.1 versus 5.7 months (HR 0.40) over platinum chemotherapy in EGFR-mutated NSCLC.

Detected & updated continuously · Source: Nebula